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Abstract
Prevalent infection with human herpes simplex 2 (HSV-2) or human papillomavirus (HPV) is associated with increased
human immunodeficiency virus (HIV) acquisition. Microbicides that target HIV as well as these sexually transmitted
infections (STIs) may more effectively limit HIV incidence. Previously, we showed that a microbicide gel (MZC) containing
MIV-150, zinc acetate (ZA) and carrageenan (CG) protected macaques against simian-human immunodeficiency virus (SHIV-
RT) infection and that a ZC gel protected mice against HSV-2 infection. Here we evaluated a modified MZC gel (containing
different buffers, co-solvents, and preservatives suitable for clinical testing) against both vaginal and rectal challenge of
animals with SHIV-RT, HSV-2 or HPV. MZC was stable and safe in vitro (cell viability and monolayer integrity) and in vivo
(histology). MZC protected macaques against vaginal (p,0.0001) SHIV-RT infection when applied up to 8 hours (h) prior to
challenge. When used close to the time of challenge, MZC prevented rectal SHIV-RT infection of macaques similar to the CG
control. MZC significantly reduced vaginal (p,0.0001) and anorectal (p = 0.0187) infection of mice when 106 pfu HSV-2 were
applied immediately after vaginal challenge and also when 56103 pfu were applied between 8 h before and 4 h after
vaginal challenge (p,0.0248). Protection of mice against 86106 HPV16 pseudovirus particles (HPV16 PsV) was significant for
MZC applied up to 24 h before and 2 h after vaginal challenge (p,0.0001) and also if applied 2 h before or after anorectal
challenge (p,0.0006). MZC provides a durable window of protection against vaginal infection with these three viruses and,
against HSV-2 and HPV making it an excellent candidate microbicide for clinical use.
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Introduction
HIV, HPV and HSV-2 constitute the three major viral STIs,
and infection with HPV [1] or HSV-2 [2] increases HIV
susceptibility. Like HIV, these viruses have no cure. Although
quadrivalent (targeting genotypes 6, 11, 16 and 18) and divalent
(targeting genotypes 16 and 18) preventive vaccines against HPV
are commercially available, HPV vaccination rates are currently
low due to many challenges, including parental autonomy and cost
[3]. Moreover, other important HPV types are not targeted, and
the vaccine requires a cold supply chain, which limits its use in
developing countries [3] and confirms the need for other
preventive modalities, such as microbicides with anti-HPV
activity.
Concrete evidence now substantiates the ability of a microbicide
to inhibit both HIV and HSV-2. The Phase 2b CAPRISA 004
trial demonstrated reduced vaginal acquisition of both viruses in
the presence of 1% tenofovir (TFV) gel and set the stage for
advancing microbicide development against HIV and broadening
the target to include co-pathogens [4].
The most advanced products in the microbicide pipeline are
based on single active pharmaceutical ingredients (APIs), specif-
ically reverse transcriptase inhibitors (RTIs) [4,5,6] (http://www.
mtnstopshiv.org/node/4546). Although single API products are
PLOS ONE | www.plosone.org 1 April 2014 | Volume 9 | Issue 4 | e94547
still being advanced, the transition to products composed of
multiple drugs with differing modes of action is gaining
momentum; especially as novel formulations, vehicles and delivery
systems are developed to enable the release of diverse compounds
[7,8]. Double and triple combinations of APIs may enhance both
the potency and breadth of anti-HIV protection as they show
synergistic activity [9] and cover many drug resistant isolates [10].
Multipurpose prevention technologies (MPTs) that simultaneously
target multiple sexual and reproductive health needs will improve
health and save resources (http://cami-health.org/documents/
2012-SAWG-Report-FinalReport.pdf). MPTs that combine APIs
to prevent different STIs and/or unwanted pregnancy are being
developed in different delivery systems, predominantly intravag-
inal rings (IVRs) (http://www.cami-health.org/documents/
Microbicides-and-Devices.pdf). Although IVRs offer women a
discrete sustained-release microbicide alternative, giving women
options is of paramount importance for adherence [11]. On-
demand products, like gels, are still a priority (http://cami-health.
org/documents/2012-SAWG-Report-FinalReport.pdf) and have
the potential to be used both vaginally and rectally.
In initial testing, the first generation MZC gel (containing the
non-nucleoside reverse transcriptase inhibitor (NNRTI)MIV-150,
Zinc acetate and Carrageenan) provided macaques up to 8 h of
complete protection against vaginal infection with SHIV-RT
[12,13]. ZC gels were highly effective at preventing high dose
HSV-2 vaginal and anorectal infection in mice [14] and even
significantly reduced vaginal SHIV-RT infection (though less
effectively than MZC [12]). Additional data suggest that CG has
activity against HPV [15,16,17,18]. Herein we demonstrate that a
new formulation of MZC modified for safety in humans is indeed
safe, and blocks vaginal SHIV-RT infection in macaques as well as
vaginal and rectal HSV-2 and HPV infection in mice. Thus, MZC
is a unique formulation protecting against HIV, HSV-2, and
HPV, warranting advancement to clinical testing.
Materials and Methods
Ethics statement for animal procedures
Housing and care of adult female Indian rhesus macaques
(Macaca mulatta) complied with the regulations under the Animal
Welfare Act, and the Guide for the Care and Use of Laboratory
Animals [19] at Tulane National Primate Research Center
(TNPRC; Covington, LA). All macaque studies were approved
by the Institutional Animal Care and Use Committee (IACUC) of
the TNPRC for macaques (#A4499-01) and complied with
animal care procedures [19,20], receiving full accreditation by the
Association for Accreditation of Laboratory Animal Care
(AAALAC #000594). All mouse studies were approved by the
IACUC of the Comparative Bioscience Center (CBC) at The
Rockefeller University (IACUC protocol # 10019, 10039 and
12563).
The macaques were socially housed until challenge and then
separated until infection status was determined. Macaques with
similar infection status (either infected or uninfected) were then
socially housed again. The housing restrictions were scientifically
justified and approved by the IACUC as part of the protocol
review. All the animals on this study were fed commercially
prepared monkey chow twice daily and supplemental foods were
provided in the form of fruit, vegetables, and foraging treats as part
of the TNPRC environmental enrichment program. The TNPRC
environmental enrichment program is reviewed and approved by
the IACUC semiannually. Extensive efforts are made to find
compatible pairs for every study group, and additional environ-
mental enrichment is provided through a variety of food
supplements and physical complexity of the housing space. A
team of 11 behavioral scientists monitored the well-being of the
animals and provided direct support to minimize stress during the
study period. The macaques were anesthetized with tiletamine/
zolazepam (8 mg/kg body weight) prior to blood draws and
biopsies and treated with buprenorophine (0.01 mg/kg body
weight) for analgesia. Preemptive and post-procedural anesthetics
and analgesics are required by the TNPRC division of veterinary
medicine for procedures that would likely cause more than
momentary pain or distress in humans undergoing the same
procedure. No macaques were sacrificed in the studies.
All mouse care procedures were in compliance with the
regulations detailed under the Animal Welfare Act [20] and the
Guide for the Care and Use of laboratory Animals [19].
Veterinarians at the TNPRC Division of Veterinary Medicine
and at the CBC at The Rockefeller University monitored animals
regularly to minimize any distress or pain.
Formulations
MZC: Step 1: A 4 L Ross double planetary mixer was charged
with 2678 ml of sterile purified water and 3.93 g of sodium
acetate. The solution was heated for 5 min at 69uC with stirring at
40 rpm. CG (93 g) was added and the mixture was stirred for 3 h
at 69uC. Step 2: The formulation was cooled to 25uC. Step 3: A
solution of 9 g of ZA in sterile purified water was added to the
formulation from step 2 and stirred for 20 min at 40 rpm. A
solution of 6 g of methyl paraben and 55.6 mg of MIV-150 in
propylene glycol (60 g) was then added and the solution was
stirred for an additional 1 h at 40 rpm. MIV-150 (C19H17FN2O3)
is a potent NNRTI that belongs to the group of phenethylthia-
zolylthiourea derivatives [21]. Step 4: If necessary, the pH of the
formulation was adjusted to 6.8 to 7.0 with either 1N NaOH or
1N HCl. Step 5: The mixture was stirred for 15 min under
vacuum to remove air bubbles. The following lot numbers were
used in our studies: 110523A1005ML, 120120A1005MR,
110921A1005ML, 120926A1005ML, 110606A1005MR and
110523A1005ML. A control 3% (w/v) CG vehicle prepared
under the same conditions but in the absence of ZA and MIV-150
was used in several experiments (Lot numbers 120111A525MR,
110509A525MR, and 110512A525). Hydroxyethylcellulose
(HEC) gel was formulated at Clean Chemical Sweden (Borla¨nge,
Sweden) as described by Tien et al [22].
Stability studies
Twenty-five gram aliquots of test gel were placed in 30 ml
polypropylene bottles that were stored under the following
conditions: 30uC/65% relative humidity, 40uC/75% relative
humidity, and 50uC/ambient humidity. Bottles were removed at
scheduled times and the gel analyzed for methyl paraben content,
MIV-150 content, osmolality, pH, viscosity, and Zn2+ content as
previously described [14].
In vivo gel distribution in macaques
To assess the distribution and spread of MZC in the macaque
reproductive tract, MRI was employed. All MRI examinations
(3D SPGR T1 weighted gradient echo with fat saturation) were
performed at 2 and 24 h after 2 ml MZC was instilled into the
vagina. Animals were anesthetized with tiletamine/zolazepam
(8 mg/kg IM) for the MRI scan (GE Signa Horizon LX1.5T with
Software 9.1; GE Healthcare, Port Washington, NY). Sagittal and
transverse images were taken to assess spread of the gel throughout
the reproductive tract.
A Microbicide to Prevent HIV, HSV-2 and HPV
PLOS ONE | www.plosone.org 2 April 2014 | Volume 9 | Issue 4 | e94547
Cells and Viruses
HeLa and Caco-2 cells (ATCC, Rockville, MD) were cultured
and/or differentiated as previously described [23]. Human
peripheral blood mononuclear cells (PBMCs) were isolated from
healthy blood donors (New York Blood Center, Long Island City,
NY) and the 363 stimulation was performed as previously
described by Trkola et al [24]. After activation, PBMCs were
grown in fresh stimulation media consisting of RPMI 1640 (Life
Technologies), 10% FBS, antibiotics at a final concentration of
50 U/ml of penicillin, 50 mg/ml streptomycin and recombinant
IL-2 at 20 U/ml (Roche, Indianapolis, IN).
L. jensenii, L. crispatus and C. albicans strain SC5413 (ATCC) were
propagated as previously described [23].
HIV and SHIV-RT. Table S1 summarized the HIV-1
laboratory strains, primary isolates, MDR isolates/clones and
SHIV-RT virus used in our experiments. The original SHIV-RT
stocks were grown in PHA activated human PBMCs. SHIV-RT
stocks were re-titered using 1746CEM cell line (NIH AIDS
Research & Reference Reagent Program), while HIV stocks were
re-titered using 363 activated human PBMCs. TCID50 were
calculated using the Reed and Muench formula. Aliquots of virus
stocks were stored at 280uC.
HSV-2 G strain. The virus was propagated in Vero cells
(ATCC) and titered using the plaque formation assay on Vero cells
as previously described [25]. Aliquots of virus stock were stored at
280uC.
HPV PsVs. HPV-16, 18 and 45 PsVs were produced
following the NCI protocol published on Dr. John Schiller’s
laboratory website http://home.ccr.cancer.gov/Lco/. For this
purpose, 293TT cells were obtained from NCI at Frederick, MD,
and the following plasmids were generously provided by Dr. John
Schiller or purchased through Addgene, Cambridge, MA: p16shell
and Addgene plasmids 37321 [17], 37323 [17] and 37328 [26].
Aliquots of virus stocks were stored at 280uC.
The pCLucf/HPV PsV stocks were titered by quantitative PCR
(qPCR) to assess the reporter plasmid (pCLucf # 37328) copy
number. Primers that target the EGFP region of pCLucf were
designed using ABI’s Primer Express software. Each reaction
consisted of 12.5 ml of 26 ABsolute Blue qPCR Sybr Green
(Thermo Scientific, Rockford, IL) master mix, 70 nM each EGFP
primer (forward GAGCTGAAGGGCATC GACTT and reverse
CTTGTGCCCCAGGATGTTG) and 5 ml of a 1:1000 dilution of
PsV stock in a reaction volume of 25 ml. Cycling conditions
consisted of an initial denaturation step at 95uC for 15 min
followed by 40 cycles of alternating 95uC for 15 seconds, 60uC for
30 seconds and 72uC for 30 seconds. Fluorescence was detected
during the elongation stage. A melting curve step was added after
the end of the cycling to assess specificity of the reaction. For
standard curves, qPCR was performed on a 10-fold dilution series
of purified pCLucf plasmid ranging from 108 copies to 10 copies
per reaction. Reactions were performed using an ABI ViiA 7
thermal cycler.
In vitro toxicity and anti-HPV PsV activity
HeLa cells were plated at 104 cells/well in 100 ml of medium
and incubated overnight at 37uC, 5% CO2 and 98% humidity.
MZC or CG was diluted in medium to obtain 26dilutions of the
appropriate dilution range to test (0.000067 to 0.00000001). The
cell culture media was then removed from the microplates and
replaced with 50 ml of the dilutions of each formulation or 50–
100 ml of medium for virus and cell controls. Dilutions were tested
in triplicate. HPV PsV stocks were thawed on ice and diluted to
107 copies/ml. Fifty ml of PsV (56105 copies) were added to all
wells with the exception of cell controls and incubated for 72 h at
37uC, 5% CO2 and 98% humidity. The cells were lysed to detect
luciferase activity using the Pierce Firefly Luciferase Glow Assay
with Pierce Firefly Signal Enhancer (Thermo Scientific) as
described by the manufacturer. Luminescence was read on a
Gemini EM microplate reader (emission 542 nm) using Softmax
Pro 3.2.1 software. Cytotoxicity for each gel formulation was
estimated using the XTT assay [27,28]. For this purpose, the
antiviral assay was mimicked but in the absence of virus. CC50 and
IC50 values were calculated using a dose-response-inhibition
analysis on GraphPad Prism v5.0c software. Therapeutic indexes
(TI =CC50/IC50) were calculated.
In vitro toxicity and anti-HIV activity in PBMCs
Activated PBMCs (26106/ml) were treated for 1 h with
dilutions of gels (triplicates) before adding 100 TCID50 of virus
and incubating overnight. To compare the anti-HIV activity of
MZC and CG in vitro this had to be presented based on gel
dilution, since there is no MIV-150 (which is the active component
in this assay) in the CG control. The supernatant was replaced
with fresh stimulation media on d 1 and 4 post infection. The p24
level in the supernatant was tested on d 7 after infection by p24
ELISA (Zeptometrix, Buffalo, NY). Cytotoxicity for each gel
formulation was estimated using the XTT assay by mimicking the
antiviral assay in the absence of virus [27,28]. CC50 and IC50
values were calculated using a dose-response-inhibition analysis on
GraphPad Prism v5.0c software. Therapeutic indexes (TI=CC50/
IC50) were estimated.
In vitro toxicity against lactobacilli and C. albicans
Diluted gel formulations and Penicillin/Streptomycin (P/S;
P= 100 U/ml and S= 100 mg/ml; Life Technologies) or ampho-
tericin B (Amph.B; 50 mg/ml; Life Technologies) were tested for
toxicity against lactobacilli and C. albicans as previously described
[23]. The lactobacilli and C.albicans were considered sensitive to
killing if the formulations caused a viability reduction equal to or
greater than 1 log10 [29].
Transepithelial electrical resistance (TEER)
The TEER assay was performed as previously described [27],
except that the media was replaced on the day of the assay with
fresh DMEM without phenol red (Life Technologies) supplement-
ed with MITO + Serum Extender (BD Biosciences). All
formulations were diluted 1:10 in the above media and 300 ml
were applied in triplicate in the upper chambers. Resistance
readings were performed at 0, 2, 4 and 6 h.
Animal studies to measure safety
Histology. Medroxypregesterone acetate (Depo-Provera,
depo)-treated Balb/C mice or fasted and anesthetized (Keta-
mine/Xylazine solution) mice were given formulations vaginally or
rectally, respectively. Dulbecco’s Phosphate-Buffered Saline (D-
PBS) was used as a no damage reference and Gynol II (www.
drugstore.com) as a reference for tissue damage. The mice were
sacrificed at 1, 6, and 24 h after gel installation, and vaginal or
rectal tissue was collected and processed [14]. Morphological
analysis was performed using hematoxylin and eosin (H&E)
staining followed by examination of the stained tissue sections to
evaluate the mucosal architecture.
HSV-2 increased susceptibility model. Following our
established method [14], 10 ml of each formulation was applied
intravaginally to depo-treated Balb/C mice daily for 7 d, and 12 h
after the last application, mice were challenged with 10 ml of 26
103 pfu of HSV-2 G. In each experiment, a placebo group (D-
A Microbicide to Prevent HIV, HSV-2 and HPV
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PBS) was used in addition to CG to compare to MZC. Beginning
on d 4 after inoculation, mice were examined and scored daily for
21 d total. Animals with symptoms of infection (hind limb
paralysis, erythema, hair loss, and/or swelling in the vaginal area)
were scored as infected and euthanized.
Animal studies to measure efficacy
Macaque efficacy and PK studies. We performed the
studies in adult female Indian rhesus macaques (Macaca mulatta)
ranging from 4–12 years old and weighing from 4–10 kg. Animals
tested negative for simian type D retroviruses, simian T cell
leukemia virus-1, and SIV prior to use in the efficacy studies.
Animals were anesthetized with ketamine-HCL (10 mg/kg) before
EDTA blood samples were taken (no more than 10 ml/kg/month)
at the indicated time points pre and post-virus challenge.
Preemptive and post-procedural analgesia was required for
procedures that would likely cause more than momentary pain
or distress in humans undergoing the same procedures. 5 wks
before vaginal virus challenge, animals received a single 30 mg
i.m. injection of depo.
For the group challenged vaginally, depo-treated macaques
were atraumatically dosed vaginally with 2 ml of MZC or CG
using a pliable French catheter for 14 consecutive days. 24 or 8 h
after the last application, they were challenged vaginally with
0.5 ml of 103 TCID50 SHIV-RT (SIVmac239 and HIV-1HxB2
RT). All animals were maintained in a supine position for 20–
30 min post-challenge to allow absorption of virus. Not only does
this approach evaluate the activity of MZC (vs. CG), since ,65%
of the CG-treated animals become infected it also provides a
measure of safety (i.e., that there is not .65% infection in the
MZC group, especially after repeated dosing). In the group
challenged rectally, macaques were dosed rectally with 3 ml of
MZC or CG using a pliable French catheter 1 h before rectal
challenge with 0.5 ml of 103 TCID50 SHIV-RT. Monkeys were
anesthetized with ketamine-HCl (10 mg/kg) prior to these
procedures. Individual animal information is summarized in
Table S2. Blood samples were transported overnight from the
TNPRC to our laboratories at the Population Council for
processing and analysis.
To approximate in vivo levels of MIV-150 in efficacy experi-
ments (direct sampling not possible), vaginal or rectal biopsies,
swabs and plasma samples were collected from a separate group of
animals treated with gels as in the efficacy studies and then MIV-
150 in those samples was quantified. Depo-treated animals
received daily applications of MZC vaginally for 2 wks. Plasma
was collected at different time points up to 24 h post-gel (n = 6),
and vaginal and cervical tissues were collected 8 h (n= 12) and
24 h (n= 6) after the last gel application. Animals received a single
application of MZC rectally, and plasma (n = 12) and rectal tissue
(n = 6) were collected 1 h later. Vaginal swabs were collected 8 h
(n = 6) and 24 h (n= 6) after last vaginal gel application, while
rectal swabs were collected 1 h (n = 6) after single rectal gel
application. Vaginal/rectal fluids were collected using a Merocel
eye spear sponge inserted into the vaginal/rectal vault. The tip of
the sponge was saturated in 1 ml sterile saline (without serum or
antibiotics) or PBS with 1% FBS and antibiotics (pen/strep) prior
to insertion to prevent injury of the mucosa. The sponge was left in
the vagina/rectal cavity for about 5 min to absorb mucosal fluid
and was rotated several times to absorb more mucosal fluid prior
to removal. Upon removal, the saturated sponge was placed
immediately back into the tube containing the 1 ml PBS or saline.
The unknown volume of native cervicovaginal or rectal fluid was
not accounted for in the final calculations of API concentrations.
We quantified MIV-150 in swabs by RIA [LLOQ, 1 ng/ml
(2.7 nM)] [12], and in plasma by LCMS/MS [LLOQ, 20 pg/ml
(54 pM)] as previously described [13]. We developed and
validated an LCMS/MS procedure for MIV-150 quantification
in tissue. Tissue samples were processed by mixing 120 ml of water,
280 ml of ACN and about 20 mg tissue sample in Lysing Matrix A
tubes (MP Biomedicals, Solon, OH). Samples were homogenized
at 60 speed for 40 seconds, 3 times using a FastPrep-24
homogenizer (MP Biomedicals, Solon, OH), followed by sonica-
tion for 20 min (Branson 3510, Danbury, CT). Samples were
centrifuged for 5 min at 5,000 rpm, and then supernatant was
transferred into a conical polypropylene tube (USA Scientific,
Orlando, FL), centrifuged for 10 min at 13,000 rpm, and used for
MIV-150 quantitation. MIV-160 (a related NNRTI with similar
chemical properties provided by Drs. Bo O¨berg and Disa Bo¨ttiger,
Medivir) was used as the internal standard at 2 ng/ml. The
compounds were separated using a ACQUITY UPLC BEH
analytical column (1.7 mm, 2.16 50 mm) (Waters, Milford, MA)
using gradient elution with a mobile phase consisting of 5% ACN
in water [A] and ACN [B], with addition of 0.1% acetic acid to
both [A] and [B], at a flow rate of 0.5 ml/min. The retention
times for MIV-150 and MIV-160 were 0.8 and 0.57 min,
respectively, with a total run time of 5 min. The analytes were
detected with a Xevo-TQs (Waters, Milford, MA) triple quadru-
pole mass spectrometer in positive electrospray ionization mode
using multiple reaction monitoring (MRM). The extracted ions
monitored following MRM transitions were m/z
369.296R224.114 for MIV-150 and m/z 343.2R198.06 for
MIV-160. The LLOQ was 111 fg on the column (0.25 pg/mg of
tissue). The overall intraday and interday assay RSD% and RE%
were ,15%.
SIVgag PCR. Dry PBMC pellets (56106 cells) were frozen
and stored at 280uC until needed [12]. Nested PCR was
performed on lysed pellets to determine the presence of SIVgag
DNA [30].
RT-PCR. Plasma viral RNA copy numbers were determined
by quantitative RT-PCR [31]. Animals were defined as infected
when they recorded.103 RNA copies/ml in at least 2 consecutive
samples within the 20 weeks post infection follow up period.
SIV Ab responses. SIV-specific Abs were monitored by
ELISA [12,32]. Ab positivity was defined as having positive OD
values over the baseline at 4 or 8 weeks post-challenge.
Detection of SHIV-RT drug resistance mutations. Drug
resistance mutations (DRMs) in the RT gene of SHIV-RT
circulating in animals that became infected during the study were
screened by sequencing plasma virus RNA using the previously
described method [33].
High HSV-2 dose challenge in mice. Vaginal and anorectal
high HSV-2 dose challenge was performed as previously described
[14].
Window of protection with low HSV-2 dose in
mice. Depo-treated mice were given 10 ml of test formulation
intravaginally at 8 or 4 h prior to HSV-2 infection as well as 2, 4
or 8 h after HSV-2 infection. Ketamine/Xylazine treated mice
were given 20 ml of test formulation in the anorectal area at the
same time points described for the vaginal application. All the
mice were challenged intravaginally with 10 ml of HSV-2 G
(56103 pfu/mouse) or in the anorectal area with 10 ml of HSV-
2 G (105 pfu/mouse). In each experiment, a placebo group (D-
PBS) was used in addition to the CG vehicle-only gel to compare
to MZC. All mice were examined and scored as described in the
‘‘HSV-2 increased-susceptibility model’’ section.
HPV-16 PsV vaginal challenge in mice. The assay was
performed to test anti-HPV activity of the MZC formulation
A Microbicide to Prevent HIV, HSV-2 and HPV
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following the procedure described by Roberts et al. [17], with the
only difference that formulation was not pre-mixed with virus
inoculum before vaginal application. Instead, 10 ml of test
formulation was inserted intravaginally 24 h, 8 h or 10 min
before challenging with 86106 copies/10 ml of HPV-16 PsV, as
well as 0.5 or 2 h after PsV challenge. In all experiments,
Conceptrol was applied 6 h before challenge as previously
described for the HPV PsV vaginal model [17]. The Conceptrol
treatment promotes abrasions in the epithelium, allowing the
binding of HPV PsV to the basement membrane. In vivo luciferase
expression was measured 24 h after intravaginal challenge by
anesthetizing the animals with isoflurane (Aerrane, Deerfield, IL),
applying 20 ml of D-luciferin (Caliper Life Sciences, Hopkinton,
MA) intravaginally, incubating 3 min and performing in vivo
imaging in the IVIS Lumina (Xenogen, Alameda, CA). Lumines-
cence signal was expressed as mean value in radiance.
HPV-16 PsV anorectal challenge in mice. Six to eight-
week-old female Balb/C mice (Charles River Laboratories) were
fasted for 24 h prior to the anorectal HPV-16 PsV challenge, but
food and water were available ad libitum following initial HPV-
16 PsV challenge. Six hours before PsV challenge, the animals
were anesthetized to both immobilize them and prevent defecation
using an IP injection of 100 ml of a solution containing: 3 ml of
dissolved Ketamine (Fort Dodge Laboratories, Fort Dodge IA),
320 ml of Xylazine (Miles Inc., Shawnee Mission KS) and
12.48 ml D-PBS. The next step was to immediately apply 30 ml
of Conceptrol gel (Revive Personal, Madison, NJ) in the anorectal
area to promote abrasions in the epithelium [17]. Mice were
anesthetized with isoflurane 6, 4 or 1 h later and challenged with
86106 copies/10 ml D-PBS of HPV-16 PsV to determine the
optimal time for Conceptrol treatment. One hour after Conceptrol
treatment rendered the best luminescence signal and was chosen
to test the MZC formulation vs. HEC placebo. Twenty ml of gel
formulations were applied at different time points before (0.5, 2
and 8 h) or after (0.5 and 2 h) PsV challenge to test anti-HPV PsV
activity. In vivo luciferase expression was measured as described in
the vaginal model but anesthetizing the animals with ketamine/
xylazine 24 and 48 h after PsV challenge and applying 20 ml of D-
luciferin in the anorectal area. All the anorectal inoculations were
performed by introducing a tip loaded with the sample in the
rectum about 0.5 cm and dispensing while retracting the tip
towards the anal canal.
CG PK in mice and CG detection. PK was performed
under the same conditions as the efficacy studies for vaginal and
rectal HPV PsV challenge but in the absence of HPV PsV. For this
purpose, vaginal and rectal washes were collected for detection of
CG from groups of six or eight animals by washing with D-PBS
(200 ml) at 0.5, 1, 2, 4, 8 or 24 h after applying 10 ml (vaginal) or
20 ml (rectal) of MZC. Vaginal or rectal washes from control mice
that did not receive MZC (n= 6 or 8 per time point) were also
collected. The unknown volume of native cervicovaginal or rectal
fluid was not accounted for in the final calculations. The in house
CG ELISA was performed to detect CG [LLOQ= 40 ng/ml].
Ninety six-well maxisorp microtiter plates (Nunc, Roskilde,
Denmark) were coated with 100 ml/well (2.5 mg/ml in D-PBS)
of custom prepared rabbit anti-CG polyclonal IgG antibody
(Pacific Immunology, Ramona, CA) overnight at 37uC. The plates
were inverted to discard the coating antibody and immediately
blocked with 200 ml/well of assay diluent (Zeptometrix) for 1 h at
37uC. The plates were then washed six times (300 ml/well) with
washing buffer (Zeptometrix). A standard curve of CG in a range
of 10,000 to 40 ng/ml was prepared in diluent assay using the 3%
(w/v) CG gel formulation described in the formulation section.
Vaginal and rectal wash samples were diluted 1:1,000 and
1:10,000 in assay diluent. All standards and samples were tested
in duplicates 100 ml/well. The plates were incubated for 1 h at
37uC followed by a washing step as described above. One hundred
ml/well (1 mg/ml) of custom prepared biotinylated rabbit anti-CG
polyclonal IgG antibody (Pacific Immunology) were added to all
wells but the blank, before incubating 1 h at 37uC. The plates
were washed again and HRP-based detection system with TMB
substrate (Zeptometrix) was used to complete the ELISA after
applying the stop solution (Zeptometrix). Absorbance was mea-
sured at 405 nm with an Emax Molecular Devices microplate
reader.
Statistical analyses
Fisher’s exact test was used for comparison of SHIV-RT
infection frequency in the different treatment groups. Since the
number of placebo macaques are limiting in our statistics, relevant
historical controls (challenged identically and using the same virus
stock) are included in addition to the real time controls as done
previously [12,13,23]. Fisher’s exact test was also used for
comparison of mouse infection after challenge with HSV-2. The
Mann Whitney U test was used for comparison of in vivo luciferase
expression in the HPV PsV mouse model. Statistical analyses were
performed using GraphPad Prism version 5.02 for Windows
(GraphPad Software, San Diego, CA). P values ,0.05 were taken
as statistically significant.
Results
MZC is stable and safe
A side-by-side comparison of different properties of the first
generation prototype gel used in previous studies [12,13] and the
modified gel evaluated in this study is shown in Table 1. Modified
MZC was stable for 12 months at 30uC/65% RH (relative
humidity) and 9 months at 40uC/75% RH. Even after 1 month at
50uC, MZC remained stable (Table 1). Previous studies have
shown that CG-based gels are shear thinning spreading gels [14].
Magnetic resonance imaging (MRI) performed 2 h after vaginal
MZC administration in macaques showed distribution of the gel
throughout the vaginal vault; gel was no longer detected by 24 h
post-gel application (Fig. S1). Additionally, no gel was detected in
the endocervix or endometrium at any time point.
Previous macaque studies showed that prototype MZC was safe,
as determined by examining vaginal pH and the cytokines and
chemokines secreted locally after repeated gel application [12]. In
this study, we expanded the safety evaluation to include several in
vitro and in vivo assays that allowed us to estimate potential damage
to epithelial integrity and toxicity towards normal microflora.
In vitro, MZC did not affect cell monolayer integrity as measured
by TEER in differentiated Caco-2 monolayers for up to 6 h, in
contrast with the rapid decrease of TEER values exerted by Gynol
II (Fig. 1A). Lactobacillus jensenii, lactobacillus crispatus and Candida
albicans viability was not significantly affected by MZC, whereas P/
S and Amph.B both significantly decreased viability of the
respective organisms (. 1 log10 reduction) (Fig. 1B and 1C).
MZC also did not drive the differentiation of unicellular yeast form
into the pathogenic multicellular filamentous form (Fig. 1C).
In vivo safety was evaluated in an HSV-2 infection enhancement
model. Following repeated vaginal gel application, mice were
challenged with a suboptimal inoculum of 26103 pfu/mouse that
infects only 50% of the control animals (D-PBS-treated) [14].
Gynol II, but not MZC, enhanced the susceptibility of mice to
HSV-2 infection (p,0.0001 vs D-PBS; Fig. 2A). In contrast, MZC
treatment significantly decreased infection in this model
(p = 0.0006 vs D-PBS).
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Histological examination of cervicovaginal and rectal mucosae
after single MZC application to mice revealed no signs of damage
to the epithelial architecture (Fig. 2B). As expected, Gynol II
profoundly damaged the cervicovaginal (peak damage at 6 h,
repaired by 24 h) and rectal (peak damage at 1 h, repaired by 6–
24 h) tissues as evidenced by epithelial sloughing and exposure of
the lamina propria [23,34].
MZC exhibits potent and broad in vitro antiviral activity
against HIV and prevents vaginal SHIV-RT infection in
macaques
MZC showed broad antiviral activity against HIV independent
of clade, tropism or phenotype (Table 2 and Table S1). To
evaluate activity without the confounding influence of the
moderate in vitro antiviral effect of CG [28], we replaced the
supernatant containing MZC or CG with fresh stimulation media
18 h after adding virus. Under these conditions, CG exhibited no
antiviral activity while MZC was still potent (IC50 values average
,1 nM based on MIV-150 concentration or , 0.0003 (1/30000)
Table 1. Formulation attributes after long term stability testing.
Property Prototype MZC Gel Modified MZC Gel
CG 3.0% 3.1%
Lambda:kappa CG 94:6 60:40
Buffer none 10 mM sodium acetate
Co-solvent 1% DMSO 2% Propylene glycol
MIV-150 50 mM 50 mM
ZA 14 mM 14 mM
Methyl paraben 0.2% 0.2%
pH 6.64 6.90
Osmolality 474 mOsmol/kg 447 mOsmol/kg
Viscosity (freshly prepared) 29,300 cP 29,900 cP
Viscosity (3 months at 30uC/65% RH) NT 35,100 cP
Viscosity (6 months at 30uC/65% RH) NT 36,200 cP
Viscosity (9 months at 30uC/65% RH) NT 34,200 cP
Viscosity (12 months at 30uC/65%RH) NT 32,600 cP
Viscosity (3 months at 40uC/75% RH) NT 22,700 cP
Viscosity (6 months at 40uC/75% RH) NT 28,200 cP
Viscosity (9 months at 40uC/75% RH) NT 24,600 cP
Viscosity (1 month at 50uC/ambient) NT 34,000 cP
Formulations were placed in 30 ml polypropylene bottles and stored at 30uC/65% RH, 40uC/75% RH, and 50uC/ambient humidity. The gels were analyzed at indicated
times for pH, viscosity, osmolality, methyl paraben content, and ZA content. The specified acceptable ranges for each parameter are indicated in each column heading.
NT = not tested.
doi:10.1371/journal.pone.0094547.t001
Figure 1. Modified MZC is safe in vitro. A) Caco-2 cell monolayer integrity. TEER was measured in differentiated Caco-2 cell monolayers after
treatment with 1:10 diluted formulations for 0-6 h. Means6 SD are shown from two independent experiments performed in triplicate. B) Lactobacilli
in vitro viability. MZC toxicity was measured by treating L. jensenii (empty bars) and L. crispatus (filled bars) with 1:10 diluted MZC vs. P/S for 30 min.
The number of colonies (mean 6 SD from three independent experiments) relative to saline 7.5% FBS, is shown as a percent. C) C. albicans in vitro
viability. MZC toxicity was measured by incubating C. albicans yeasts with 1:10 diluted MZC vs. Amph.B for 2 h. Left axis (filled bars) represents the
numbers of colonies counted for each condition and expressed as % colonies relative to the Sabouraud dextrose broth (SB) control (set as 100%).
Right axis (empty bars) is the number of viable yeasts counted and shown as the percentage relative to the SB-treated controls. Means 6 SD of 5
independent experiments are summarized.
doi:10.1371/journal.pone.0094547.g001
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based on gel dilution since it is being compared to CG). These
potent IC50 values combined with the lack of toxicity (CC50.0.05,
the lowest dilution tested) result in high therapeutic index (TI)
values (Table 2) against a spectrum of HIV strains including
multidrug resistant strains/clones containing multiple DRMs. The
only exceptions were two isolates (S18-7d7 and OL-1/4(II)d4) that
each contained a combination of two NNRTI mutations that
decreased MIV-150 susceptibility (K101E+Y181I and K103N+
L100I, respectively) (Table 2 and Table S1).
In macaques treated vaginally or rectally with MZC, we
quantified MIV-150 in plasma, mucosal tissues, and swabs. MIV-
150 was detected in the plasma within 0.5 h of MZC treatment,
regardless of the route of administration (Fig. 3A). There was no
significant difference between plasma MIV-150 levels 0.5–1 h
after vaginal and rectal application (of 2 and 3 ml gel,
respectively). After vaginal application (where later time points
were measured), plasma MIV-150 peaked between 1–4 h post-gel
and then declined to undetectable levels within 24 h with a half-
life of approximately 8 h. We have previously shown that MIV-
150 has an IC50 and IC90 of 0.9 nM and 1.9 nM respectively
against SHIV-RT in PBMCs [35]. MIV-150 could be detected in
the cervical (606 IC50 and 306 IC90) and vaginal (66 IC50 and
36 IC90) tissues 8 h post vaginal MZC application (Fig. 3B), but
this was significantly reduced within 24 h (vaginal p = 0.0030 and
cervix p= 0.0237). MIV-150 was present in vaginal swabs at high
concentrations (10006 IC50) 8 h post-gel but had declined below
the limit of detection by 24 h (Fig. 3C). In rectally treated animals,
MIV-150 was detected in both the rectal tissue and rectal fluid 1 h
after gel administration (Fig. 3B and 3C).
MZC reduced SHIV-RT infection by the vaginal route (Fig. 4
and Table S2) with 6/8 real time CG controls becoming infected
(75%, Table 3). This frequency of infection is slightly higher but
not significantly different from the overall infection rate (64%) in
CG treated animals from our previous studies of prototype and
modified gels [12,13,35]. MZC provided complete protection (0/7
infected, 100% protection) when applied 8 h before challenge
(Fig. 4A), but 47% when the animals were challenged 24 h after
application (6/17 infected). Animals that became infected in the
24 h group exhibited similar viral loads overall to the infected CG
controls (Fig. 4B). Protection in the 8 h group was highly
significant vs CG (p= 0.0022 Fig. 4C), and the 47% protection
after 24 h approached but did not reach significance (p= 0.0566)
(Table 3). DRMs were not detected in the RT gene of SHIV-RT
circulating in infected animals (Table S3).
Prior studies using prototype MZC rectally revealed that there
was less protection rectally than vaginally [13], possibly due to the
more efficient transmission of immunodeficiency viruses across the
rectal mucosa. Because rectal microbicide gels are likely to be used
in a coitally dependent (on demand) manner in which they double
as lubricants (most probably needing intrarectal application with
rectal applicators), we decided to apply modified MZC only 1 h
prior to challenge. Unfortunately, low-level infection in the CG-
treated group (1/4 infected) resulted in an inability to detect
protection by MZC gel (p = 0.45) even though none of the animals
Figure 2. In vivo application of MZC does not compromise epithelial integrity or increase HSV-2 susceptibility. A) HSV-2 enhancement
model. Balb/C mice (n = 40 per group) were depo-treated 7 d before starting vaginal application of each formulation daily for 7 d, followed by HSV-2
G challenge 12 h post-last gel. Percent of uninfected animals over time is shown (*P,0.05 vs. D-PBS, Fisher’s exact test). B) Epithelial integrity testing.
Depo-treated (vaginal dosing) and fasted (rectal dosing) mice were treated with MZC, D-PBS, or Gynol II. At 1, 6 and 24 h post-application, mice were
euthanized, and the entire reproductive or rectal tract was surgically excised for morphological analysis. Pictures (206 magnification) are
representative of six sections from two to three animals per group.
doi:10.1371/journal.pone.0094547.g002
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(0/5) became infected (Fig. 4D). Of note, prior studies showed that
this SHIV-RT inoculum infects 100% of the animals when
administered in the presence of an inert MC placebo gel and that
there was limited impact of CG on infection when applied 8–24 h
prior to rectal challenge (Table 3 [13,23]). Thus, the blocking
effect of CG against rectal SHIV-RT infection when given 1 h
prior to challenge did not allow us to distinguish the activity of
MZC. But MZC is safe rectally as it had no adverse (enhancing)
Table 2. Antiviral Activity of MZC and CG against HIV-1 in PBMCs.
HIV-1 IC50 gel dilution (95% confidence interval) TI (CC50.0.05)
MZC CG MZC CG
NL4-3 0.0002 (0.00008 to 0.0007) ,0.001 .250 .50
92UG029 0.0004 (0.0003 to 0.0005) .0.0025 .125 ND
91US056 0.0004 (0.0002 to 0.0007) .0.0025 .125 ND
92BR014 0.0003 (0.0001 to 0.0007) .0.0025 .166.7 ND
92HT593 0.0001 (0.00005 to 0.0002) .0.0025 .500 ND
97ZA009 0.0001 (0.00009 to 0.0002) .0.0025 .500 ND
97USNG30 0.0006 (0.0005 to 0.0009) .0.0025 .83.3 ND
96USNG31 0.0006 (0.0002 to 0.003) .0.0025 .83.3 ND
CMU06 0.0001 (0.00005 to 0.0002) .0.0025 .500 ND
92TH020 0.00006 (0.00004 to 0.0001) .0.0025 .833.3 ND
93TH051 0.0004 (0.0002 to 0.001) .0.0025 .125 ND
35764-2 0.00008 (0.00003 to 0.0002) 0.0004 (0.0002 to 0.0011) .625 .125
7295-1 0.0005 (0.0004 to 0.0007) 0.001 (0.0002 to 0.009) .100 .50
29129-2 0.0002 (0.00009 to 0.0003) .0.0025 .250 ND
56252-1 0.0005 (0.0002 to 0.0014) .0.0025 .100 ND
4755-5 0.0002 (0.0001 to 0.0005) .0.0025 .250 ND
1617-1 0.0001 (0.00006 to 0.0004) 0.0005 (0.0002 to 0.0017) .500 .100
7324-4 0.0003 (0.0002 to 0.0005) .0.0025 .166.7 ND
7324-1 0.0001 (0.00007 to 0.0003) .0.0025 .500 ND
8415-2 0.0004 (0.0001 to 0.0012) .0.0025 .125 ND
6463-13 0.00004 (0.00002 to 0.0001) .0.0025 .1250 ND
7136-1 0.0003 (0.0001 to 0.0009) .0.0025 .166.7 ND
V16770-2 0.0005 (0.0004 to 0.0007) 0.0007 (0.0003 to 0.0018) .100 .71
V17763-5 0.0004 (0.0001 to 0.0016) 0.0004 (0.0001 to 0.0007) .125 .125
W1023892-2 0.0002 (0.00006 to 0.0005) 0.0005 (0.0002 to 0.0015) .250 .100
J18-1(2) 0.0002 (0.0001 to 0.0007) .0.0025 .250 ND
S18-7d7 .0.0025 .0.0025 ND ND
OL-1/4(II)d4 .0.0025 .0.0025 ND ND
C18-15d7 0.0015 (0.0011 to 0.0019) .0.0025 .33.3 ND
ND= Not determined
doi:10.1371/journal.pone.0094547.t002
Figure 3. MIV-150 local and systemic levels after vaginal and rectal application. Macaques were treated vaginally with MZC daily for 2 wks
or once rectally. A) MIV-150 was measured by LCMS/MS in the plasma of vaginally (n = 6, filled circles) and rectally (n = 6, filled squares) treated
macaques at various time points after the last gel application. B) Tissue biopsies (n = 12 per time point/type of tissue) and C) swabs (n = 6 per
condition) were collected at the indicated times following the last gel and MIV-150 was measured (by LCMS/MS for tissues and RIA for swabs). The
mean (6 SD) concentrations of MIV-150 for each treatment group are shown (rectal, R; vaginal, V; cervical, C).
doi:10.1371/journal.pone.0094547.g003
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effects that resulted in more animals becoming infected compared
to the CG controls.
MZC protects mice against vaginal and anorectal HSV-2
infection
MZC applied 10 min before challenge, effectively blocked
HSV-2 infection in stringent, high viral dose (106 pfu) vaginal
(1000 50% lethal dose (LD50)) and anorectal (10 LD50) mouse
models. There was a significant decrease in infection after vaginal
(65% uninfected, p ,0.0001 vs. D-PBS or CG) and anorectal
(55% uninfected, p = 0.0187 vs. D-PBS) challenge (Fig. 5A).
Supporting initial stability testing (Table 1), MZC that was aged
for 7 months at 40uC was comparably active against vaginal
challenge (Fig. 5A). Under less stringent conditions (56103 pfu/
mouse), we determined the window of protection by applying
MZC, CG or D-PBS at different times before or after viral
challenge. A significant decrease in the percentage of mouse
infection vs. D-PBS was observed when MZC was administered
vaginally between 8 h before (p = 0.0038) and 4 h after
(p = 0.0248) virus challenge (Fig. 5B). A blocking effect of CG
was seen with this lower inoculum. When the same experiment
was performed for HSV-2 anorectal challenge, no significant
protection was seen when MZC was applied at any of the time
points tested (data not shown), except for 10 min before HSV-2
challenge (Fig. 5A).
Breadth, high potency and durability of the anti-HPV
effect of MZC in mice
CG has been shown to block HPV PsV infection [15,17,18]. In
vitro, MZC was active against three of the most predominant high-
risk HPV genotypes (16, 18 and 45) at high gel dilutions, with
IC50 values at dilutions between 1/107 and 1/108 (corresponding
to CG concentrations between 1 and 20 ng/ml) (Fig. 6A). None of
the MZC dilutions tested in HeLa cells were toxic (CC50.0.017,
based on gel dilution), which translates to TI values .17,000.
Since MZC was more potent against HPV-18 and 45 than HPV-
16, HPV-16 was used as a more stringent test for in vivo use.
MZC fully protected mice when applied 8 h before vaginal
HPV-16 PsV challenge and still significantly reduced infection
when applied 24 h before or 2 h after challenge (Fig. 6B; earliest/
latest time points tested). This coincided with the levels of CG in
vaginal washes becoming lower after 24 h (10.766.8 mg/ml), with
an average of 44.5610.9 mg/ml CG being present after 8 h
(Fig. 6C).
To evaluate the activity of MZC against anorectal HPV
infection, we established an anorectal HPV16 PsV murine model
based on the vaginal model [17] and our experience with the
anorectal HSV-2 mouse model [14]. As anticipated from the rapid
damage observed after rectal application of Gynol II (Fig. 2B), we
achieved consistent HPV-16 PsV infection when Conceptrol (4%
Nonoxynol 9 like Gynol II) was applied rectally 1–6 h before
challenge (Fig. 7A). Detection of the PsV by luminescence
(radiance) was significantly higher (p,0.0001) under this condition
(or even when applying Conceptrol 6 or 4 h before PsV challenge)
compared to animals not treated with Conceptrol (Fig. 7A).
Although there was no significant difference in radiance between
6, 4 and 1 h Conceptrol pre-treatment (p. 0.306), we decided to
use the 1 h timing since the radiance values were more consistent
at this time. Under these conditions, MZC protected against HPV-
16 PsV anorectal challenge when applied between 2 h before and
2 h after HPV-16 PsV challenge (p,0.0006) (Fig. 7B). This
corresponds to CG levels in rectal swabs that averaged 271 mg/ml
(Fig. 7C). Notably, although CG was not detectable in the rectal
swabs after 8 h (probably due to the dilution factor and the ELISA
LLOQ), animals were still significantly protected against infection
(albeit to a lesser degree than at the earlier time points).
Figure 4. MZC completely protects against SHIV-RT infection vaginally for up to 8 h and rectally for 1 h. A) MZC or CG was
administrated vaginally daily for 2 wks followed by vaginal challenge 8 or 24 h after the last gel application. The number of animals in each treatment
group is indicated. For CG, this includes 8 real time and 14 historical controls. Plasma viral loads for each animal are shown over time. B) Mean (6
SEM) plasma viral load of infected animals from each group in (A). C) The percent infection in each of the different treatment groups. D) MZC or CG
was administrated once rectally followed by rectal challenge 1 h later. Plasma viral loads are shown for each animal over time. The number of animals
in each treatment group is indicated.
doi:10.1371/journal.pone.0094547.g004
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Discussion
Infection with either of the highly prevalent STIs HSV-2 or
HPV enhances susceptibility to HIV acquisition [1,2]. MPTs that
target multiple organisms offer a unique, single product platform
to prevent these intersecting diseases. We have modified a
combination MZC gel for use in humans that is safe and exhibits
broad spectrum, potent and durable protection against HIV,
HSV-2, and HPV. Moreover, MZC was modified with a co-
solvent more appropriate for use in humans (propylene glycol vs.
DMSO used in the prototype) in preparation for clinical testing.
MZC was safe in all the in vitro and in vivo assays performed. The
(a) unaltered TEER values, (b) lack of toxicity to Lactobacillus sp.
and C. albicans, (c) absence of damage to the architecture of
mucosal tissues and (d) lack of increase in susceptibility to HSV-2
correlates with results obtained with the modified ZC gel [23].
Further supporting the safety of this gel for both vaginal and rectal
application are the data showing protection against SHIV-RT
following daily vaginal application and the lack of increased rectal
SHIV-RT infection with gel use. MZC contains only 0.002%
MIV-150 with 0.3% ZA and 3% CG. ZA is generally recognized
as safe (GRAS), and no toxicity has been seen in rabbits after daily
vaginal dosing with a 90 mM zinc solution or zinc-loaded sponges
for 10 d [36,37]. Some adverse effects have been documented after
oral, nasal or vaginal administration of zinc salts [38,39,40].
Figure 5. MZC protects mice against vaginal and anorectal HSV-2 infection. A) Depo-treated (vaginal) or untreated (anorectal) Balb/C mice
were challenged with 106 pfu HSV-2 10 min after applying the indicated formulations (n = 20/formulation). The percentages of uninfected animals
over time, based on symptoms, are shown for each treatment group (*P,0.05 vs. D-PBS and CG, Fisher’s exact test). B) Depo-treated Balb/C mice
were treated with 10 ml of the indicated formulations intravaginally at different time points before or after HSV-2 challenge with 56103 pfu (n = 20/
formulation). The percentages of uninfected animals are shown for each time of gel dosing relative to challenge (*P,0.05 vs. D-PBS, Fisher’s exact
test).
doi:10.1371/journal.pone.0094547.g005
Figure 6. MZC has potent anti-HPV activity in vitro and prevents HPV-16 PsV vaginal infection in mice. A) The anti-HPV-16 (open circles),
18 (open trianbles) and 45 (open squares) IC50 values (shown as a vertical dotted line within the 95% confidence interval) were estimated using the
luciferase assay in HeLa cells. All gel dilutions were tested in triplicate. B) Depo-treated Balb/C mice were given the indicated formulations (HEC
placebo or MZC) intravaginally at different time points before HPV-16 PsV challenge (15 animals/treatment). In vivo luciferase expression was
measured 24 h after challenge using the IVIS Lumina and is expressed as mean luminescence in photons per second per centimeter square per
steridian6 SD (*P,0.05 vs. HEC, Mann Whitney U test). C) CG levels (mean mg/ml6 SD) in vaginal washes from mice treated intravaginally with MZC
were measured by ELISA at 1, 2, 4, 8 and 24 h post-gel (n = 6 per time point).
doi:10.1371/journal.pone.0094547.g006
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However, the events were linked to doses of zinc salts (200 mM)
that far exceed those in our MZC formulation (14 mM). CG is
also considered GRAS, has been shown to be safe and acceptable
for topical use in humans [41,42,43,44,45,46,47], has good
physical/rheological properties for a microbicide [14] and
possesses intrinsic antiviral activity [15,16,17,18].
Vaginal susceptibility to SHIV-RT was not significantly affected
by the altered gel composition. Infection frequency in the CG-
treated group was not significantly higher (p = 1.000) with
modified (6/8, 75%) compared to prototype (9/14, 64.3%) gel.
Modified MZC gel exerted time dependent protection against
SHIV-RT. In accordance with this, significantly more MIV-150
was detected in the vaginal (p = 0.003) and cervical (p = 0.0237)
tissues, the vaginal swabs (p = 0.0115) and the plasma (p= 0.0139)
at 8 h compared to 24 h post-last gel. No infections occurred when
animals were challenged vaginally 8 h after the last MZC
application for both the prototype and modified formulations (0/
7 vs. 0/7) [12,13]. Although there was no significant difference at
24 h (2/14 vs. 6/17, p= 0.239), the modified formulation was not
as protective as the prototype at this time point. In agreement with
the infection data at 8 h, the two formulations resulted in similar
levels of MIV-150 in the vaginal tissue 8 h post-last gel (mean 6
SD 0.334760.1872 for prototype vs. 0.295860.1112 for modified,
p = 0.6451) as well as in the vaginal swabs (mean 6 SD 74.6669.8
vs. 57.3675.4, p = 0.7922). Notably, significantly less MIV-150
was detected in the cervix 8 h after application of the modified
compared to prototype gel despite retaining complete protection
(mean 6 SD 0.627460.2439 vs. 0.0350560.007339, p = 0.0043).
Although no significant differences in tissue pharmacokinetic (PK)
were found 24 h post-last gel, less MIV-150 was detected in the
vagina 24 h after application of modified MZC vs. prototype, and
significantly less MIV-150 was present in the vaginal swabs (mean
6SD 2.865.7 vs. 22.3621.3, p = 0.0181) explaining the finding of
reduced protection by modified MZC gel at the 24 h time point
and the absence of gel in the vagina by MRI. Importantly, a single
application of the prototype MZC gel fully protects when
administered 8 h before vaginal SHIV-RT challenge in macaques
[13]. The rationale for using the repeated dosing regimen in this
study was to simultaneously test safety alongside the gel’s efficacy
in macaques. Daily application allowed us to observe any
detrimental effects that could cause an enhancement in SHIV-
RT infection as is seen in the increased susceptibility model for
HSV-2.
Unfortunately, we were not able to observe a significant effect of
MZC gel on rectal SHIV-RT infection due to the blocking activity
of CG when applied close to the time of challenge. The activity of
CG in this model is likely a combination of a non-specific barrier
effect of the gel due to coating of the epithelium coupled with some
characteristic polyanion blockade of cell-virus interactions [48]. Its
time dependence is clear: 1/4 animals became infected when the
gel was applied 1 h before challenge compared to 2/3 with gel
applied 8 h pre and 3/3 infected with gel applied 24 h pre
challenge [13]. The anti-HIV effect of CG in this model is further
supported by earlier work demonstrating reliable infection of
placebo MC gel-treated animals (4/4) [30]. As a result of the CG
blocking effect, nothing can be formally concluded from these data
about the gel’s efficacy rectally, but MZC did not enhance
infection when used close to the time of challenge indicating its
safety as a rectal product.
Figure 7. MZC prevents HPV-16 PsV anorectal infection in mice. A) Ketamine/xylazine-anesthetized Balb/C mice were treated in the anorectal
area with Conceptrol or D-PBS (no Conceptrol). Mice were challenged with HPV-16 PsV to determine the optimal time for conceptrol treatment that
gives the best luminescence signal. B) Ketamine/xylazine-anesthetized Balb/C mice received Conceptrol in the anorectal area and were treated with
the indicated formulations (HEC placebo for HPV-16 PsV control or MZC) in the anorectal area at different time points before and after HPV-16 PsV
challenge (15 animals/treatment). (A and B) In vivo luciferase expression was measured 48 h after challenge using the IVIS Lumina and is expressed as
mean luminescence in photons per second per centimeter square per steridian + SD (*P,0.05 vs. HEC, Mann Whitney U test). C) CG PK in rectal
washes from mice treated with MZC formulation was determined at 0.5, 2, and 8 h (n = 6 or 8 per time point) after MZC application. The graph shows
CG concentration (mean mg/ml 6 SD) per time point.
doi:10.1371/journal.pone.0094547.g007
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The anti-HIV activity of MZC covers a broad array of primary
isolates in vitro, including those from different clades with distinct
phenotypes based on co-receptor usage and cell tropism. The only
viruses tested in this study which were not susceptible to inhibition
by MZC possess double NNRTI-associated mutations: OL-1/
4(II)d4, a mutant with more than 20 DRMs, expresses an RT with
K101E and Y181I, and S18-7d7 expresses an RT with L100I and
K103N. However, three other isolates with double or triple
NNRTI-associated RT mutations (V16770-2, V17763-5,
W1023892-2) were efficiently blocked. Importantly, these in vitro
experiments using cell lines may exclude any direct or indirect
immunomodulatory effects of ZA [49,50,51,52,53], which could
boost the gel’s potency against isolates with DRMs. Additionally,
the full consequences of HIV drug resistance in the context of
prevention are not yet fully understood and could be less
significant than in a treatment setting [54,55].
We have previously shown that combining ZA with CG results
in synergistic antiviral activity against HSV-2 [14]. In this first
testing of MZC against HSV-2 in the mouse model, we
demonstrated significant anti-HSV-2 activity vaginally under
stringent conditions in which mice were inoculated with 106 pfu
of virus. Other microbicide candidates with anti-HSV-2 activity
have not shown this level of protection in mice under such
stringent conditions [56,57,58]. Protection against HSV-2 by
MZC lasted up to 8 h after gel application when challenging with
56103 pfu. Post-challenge protection in this model lasted up to
4 h. The in vivo activity of MZC against HSV-2 in this study
correlates well with the activity of other zinc-containing formu-
lations we have studied [14,23]. Not surprisingly, due to the lack of
anti-HSV-2 activity by the NNRTI MIV-150, the frequency of
infection seen with MZC (7/20 vaginal and 9/20 anorectal) is not
significantly different (p.0.320) from that seen for prototype (5-6/
18 vaginal and 5-8/20 anorectal) [14] or modified (4/20 vaginal
and 8/20 anorectal) ZC gels [23].
HPV-16 and 18 are the most oncogenic HPV genotypes,
associated with 75% of cervical cancers, 50% of vulvar cancer, 50–
75% of vaginal cancers and 80% of anal cancer [3]. Modified
MZC was potent in vitro against HPV-16 and 18 as well as 45,
demonstrating a good breadth of protection. The IC50 values
against HPV are about a thousand-fold more potent than those
described for CG against HIV [28]. The CG vaginal PK data
indicate that CG concentrations in the vaginal lumen above
50 mg/ml (observed 8 h after gel application) may be needed to
achieve full protection in vivo as shown in the mouse model at the
same time point. However, the lower concentrations (,10 mg/ml)
seen at 24 h after gel application, may still significantly decrease
infection, representing more than a thousand-fold higher CG
concentration compared to the in vitro IC50 value against HPV-16
PsV. The in vivo model shows about a 50% reduction in infection
when concentrations of CG are about a 1000-fold higher than the
in vitro IC50 values. This difference could be due to different
multiplicities of infections between the in vivo and in vitro model
what can impact the antiviral activity of CG. It has been shown
that the IC50s for the various types of CG occur under conditions
where there is a slight mass (or molar) excess of CG over L1 (HPV
capsid protein) [15]. If more virus is added, the IC50 is expected to
increase. A partial but significant reduction in infection was also
observed when the gel was applied 2 h after PsV challenge. These
results are in accordance with other in vitro data indicating that CG
may block HPV post-challenge [15]. Another important result that
supports the testing of CG as a potential microbicide against HPV
comes from the Carraguard Phase 3 trial. The prevalence of high-
risk HPV infection observed in compliant users was significantly
lower compared to compliant placebo users [16].
To our knowledge, this is the first description of an anorectal
mouse model for infection with HPV PsV. HPV infection in the
anorectal area has been widely documented in humans [59]. Our
findings support a model in which papillomaviruses from different
species and with different tissue tropisms may share the same
initial interactions with basal epithelial cells [60], allowing PsV
binding and reporter genome delivery into these cells regardless of
their anatomical location (vaginal, anorectal or dermal).
The efficacy results in the different animal models tested herein
demonstrate the high potency and durability of the antiviral effect
of MZC against the three most important viral STIs. The results
suggest the potential for MZC to be not only a clinically useful,
coitally dependent (on demand) vaginal microbicide with a broad
window of protection (at least for vaginal application), but also an
effective method of post-exposure prophylaxis for the prevention
of HPV and HSV-2. Rectally, MZC needed to be applied much
closer to the time of challenge to be effective against each virus.
However, rectal microbicide gels will likely double as lubricants
(which may also increase their acceptability [61]), and application
close to the time of exposure is expected.
The battery of assays, used in this manuscript to evaluate the
microbicide candidate, has been widely described in the literature
[12,13,14,17,23,24,28,29,30,34,35,57,62,63,64,65,66,67,68]. Ad-
ditional work has been done in terms of preclinical evaluation of
MZC safety including a 14 day rabbit vaginal irritation assessment
without any adverse effects (unpublished). We recognize the
limitations of the assays described in this manuscript, including the
need for validation in human trials [65,66,69]. To this end a Phase
1 safety trial is planned to start early 2014 to evaluate safety and
PK of MZC. The in vivo models described in this paper, using depo
treatment, extremely high viral doses for challenge and treatment
with surfactant agents to expose viral targets, represent highly
stringent models. All these conditions may favor the failure of a
promising microbicide agent, but the MZC formulation still
showed a potent antiviral activity.
While this is a proof of concept study, there are some caveats
related to gel formulations and poor adherence that has been seen
in some vaginal microbicide clinical trials [45,70]. Additionally,
gels are designed for use around time of intercourse. We are
currently exploring the formulation of MZC in intravaginal rings
and nanofibers to provide sustained release of the APIs and
potentially improve their acceptability. Taken together, our results
demonstrate that MZC is a promising microbicide combination
that should be advanced for clinical testing.
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Figure S1 MRI detection of MZC spreading in the
macaque reproductive tract. MRI was performed 2 and
24 h after vaginal MZC administration in two macaques. Transverse
(upper panels) and sagittal (lower panels) images were taken to assess
spread of the gel throughout the vaginal vault. The arrows show the
detection ofMZC gel at 2 h but not at 24 h. The images shown in the
panel are representative of 20 tranverse and 20 sagittal images.
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